The Recall Desk

Hazard

Allergic Reaction recalls

206 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
206
Critical
5
Severe
179
Most recent
2025-12-03

Of the 206 allergic reaction recalls we have scored against our rubric, 5 (2%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 179 (87%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergic reaction recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

76–100 of 206

  • SevereFDA (Drugs)·D-731-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imiquimod Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Imiquimod active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imiquimod active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-728-2015·2015-04-29

    Attix Pharmaceuticals Recalls Idebenone Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Idebenone active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Idebenone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-754-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levetiracetam Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levetiracetam active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Levetiracetam active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-908-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfisoxazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfisoxazole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Sulphafurazole (Sulfisoxazole) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-945-2015·2015-04-29

    Attix Pharmaceuticals Recalls Trimeprazine Tartrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Trimeprazine Tartrate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Trimeprazine Tartrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-603-2015·2015-04-29

    Attix Pharmaceuticals Recalls Crotamiton API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Crotamiton active pharmaceutical ingredient due to potential penicillin cross-contamination from shared facility repackaging.

    Product
    Crotamiton active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-510-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ambroxol HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ambroxol HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Ambroxol HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-792-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methylprednisolone Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methylprednisolone Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methylprednisolone Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-849-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Acetate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to a risk of penicillin cross-contamination.

    Product
    Potassium Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-553-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bupropion HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bupropion HCI active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Bupropion HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-573-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cetirizine HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cetirizine HCI active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Cetirizine HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-775-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mefloquine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mefloquine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mefloquine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-681-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flunarizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flunarizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Flunarizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-701-2015·2015-04-29

    Attix Pharmaceuticals Recalls Guanabenz Acetate Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Guanabenz Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Guanabenz Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-807-2015·2015-04-29

    Attix Pharmaceuticals Recalls Montelukast Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Montelukast Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Montelukast Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-738-2015·2015-04-29

    Attix Pharmaceuticals Recalls Isoxsuprine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Isoxsuprine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Isoxsuprine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-555-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcipotriene Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Calcipotriene active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcipotriene active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-747-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lamotrigine Ingredient Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling lamotrigine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Lamotrigine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-957-2015·2015-04-29

    Attix Pharmaceuticals Recalls Zinc Pyrithione Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Zinc Pyrithione active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.

    Product
    Zinc Pyrithione active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-920-2015·2015-04-29

    Terbinafine Base Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Terbinafine Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Terbinafine Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-883-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rocuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rocuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Rocuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-687-2015·2015-04-29

    Attix Pharmaceuticals Recalls Fluprostenol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Fluprostenol active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Fluprostenol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-700-2015·2015-04-29

    Glipizide API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Glipizide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Glipizide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-647-2015·2015-04-29

    Attix Pharmaceuticals Recalls EDTA Dipotassium Magnesium Salt Dihydrate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    EDTA Dipotassium Magnesium Salt Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-771-2015·2015-04-29

    Attix Pharmaceuticals Recalls Magnesium Stearate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Magnesium Stearate pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Magnesium Stearate pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide